dr. essel discusses adverse events of bevacizumab in ovarian cancer
Published 6 years ago • 536 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
1:05
dr. essel discusses long-term bevacizumab in ovarian cancer
-
1:08
dr. essel on repeat use of parp inhibitors in ovarian cancer
-
8:15
bevacizumab in ovarian cancer
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
4:03
upfront bevacizumab in advanced ovarian cancer
-
1:40
dr. burger on the toxicity profile of bevacizumab in ovarian cancer
-
1:06
dr. jason konner discusses bevacizumab in ovarian cancer
-
1:15
safety findings of long-term bevacizumab for patients with ovarian cancer
-
2:19
dr. arend on fda approval of frontline bevacizumab in ovarian cancer
-
6:04
when to add bevacizumab for recurrent ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
4:54
bevacizumab in recurrent ovarian cancer
-
1:59
dr. gilbert on the safety profile of mirvetuximab soravtansine/bevacizumab in ovarian cancer
-
1:12
dr. herzog on the optimal use of bevacizumab in patients with ovarian cancer
-
7:32
bevacizumab for recurrent ovarian cancer
-
7:24
ovarian cancer: maintenance following frontline bevacizumab
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
3:13
dr. herzog on the fda approval of olaparib/bevacizumab as frontline maintenance in ovarian cancer
-
1:08
dr. burger on the use of bevacizumab in ovarian cancer